Skip to main content
CGEM
NASDAQ Life Sciences

Velinotamig Drives Complete Renal Responses in Refractory SLE; 8 of 9 Patients Improve

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.51
Mkt Cap
$727.852M
52W Low
$6.732
52W High
$23.19
52W Position info
71% above low
Off High info
50% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CGEM sits 71% above its 52-week low of $6.732.

Summary

Cullinan's BCMAxCD3 T cell engager velinotamig produced clinically meaningful disease-activity reductions in 8 of 9 evaluable refractory SLE patients, with 4 of 7 proteinuric patients hitting complete renal response within 24 weeks. Safety held up: no dose-limiting toxicities, no ICANS, and no Grade 3 or higher CRS, with the two CRS events limited to Grade 1/2. This is the ACR Convergence readout Cullinan flagged in its September 24 data-calendar announcement, and it lands as the first clinical validation of the autoimmune T cell engager thesis beyond the oncology franchise. The company's lead asset remains zipalertinib, whose NDA submission started October 1 under the RTOR pathway, so velinotamig is upside optionality rather than the base case. Data are early — 12 patients treated, 9 evaluable, interim cutoff September 8 — and the program is licensed ex-Greater China from Genrix Bio, with a separate subcutaneous Phase 1b/2a running in ITP and warm AIHA.

At the time of this announcement, CGEM was trading at $11.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $727.9M. The 52-week trading range was $6.73 to $23.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $11.51 info
Change: -$1.84 (-14%) info
Market Cap: $727.852M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $11.51 info
Change: -$3.04 (-21%) info
Market Cap: $727.852M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $11.51 info
Change: -$5.37 (-32%) info
Market Cap: $727.852M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $11.51 info
Change: -$9.09 (-44%) info
Market Cap: $727.852M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $11.51 info
Change: -$9.60 (-45%) info
Market Cap: $727.852M info